首页> 外文期刊>BMC Medicine >Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry
【24h】

Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry

机译:心理治疗或抑郁用药?使用个体症状Meta-Analys来获得个性化精神病学的面向症状的治疗(分类)度量

获取原文
获取外文期刊封面目录资料

摘要

Antidepressant medication (ADM) and psychotherapy are effective treatments for major depressive disorder (MDD). It is unclear, however, if treatments differ in their effectiveness at the symptom level and whether symptom information can be utilised to inform treatment allocation. The present study synthesises comparative effectiveness information from randomised controlled trials (RCTs) of ADM versus psychotherapy for MDD at the symptom level and develops and tests the Symptom-Oriented Therapy (SOrT) metric for precision treatment allocation. First, we conducted systematic review and meta-analyses of RCTs comparing ADM and psychotherapy at the individual symptom level. We searched PubMed Medline, PsycINFO, and the Cochrane Central Register of Controlled Trials databases, a database specific for psychotherapy RCTs, and looked for unpublished RCTs. Random-effects meta-analyses were applied on sum-scores and for individual symptoms for the Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) measures. Second, we computed the SOrT metric, which combines meta-analytic effect sizes with patients’ symptom profiles. The SOrT metric was evaluated using data from the Munich Antidepressant Response Signature (MARS) study (n?=?407) and the Emory Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study (n?=?234). The systematic review identified 38 RCTs for qualitative inclusion, 27 and 19 for quantitative inclusion at the sum-score level, and 9 and 4 for quantitative inclusion on individual symptom level for the HAM-D and BDI, respectively. Neither meta-analytic strategy revealed significant differences in the effectiveness of ADM and psychotherapy across the two depression measures. The SOrT metric did not show meaningful associations with other clinical variables in the MARS sample, and there was no indication of utility of the metric for better treatment allocation from PReDICT data. This registered report showed no differences of ADM and psychotherapy for the treatment of MDD at sum-score and symptom levels. Symptom-based metrics such as the proposed SOrT metric do not inform allocation to these treatments, but predictive value of symptom information requires further testing for other treatment comparisons.
机译:抗抑郁药物(ADM)和心理治疗是对主要抑郁症(MDD)的有效治疗方法。然而,如果治疗在症状水平的有效性不同以及症状信息是否可用于通知治疗分配,则尚不清楚。本研究综合了ADM与心理治疗的随机对照试验(RCT)对症状水平的对比效果信息,并开发和测试精确治疗分配的症状取向治疗(分类)度量。首先,我们对RCT进行了系统的审查和荟萃分析,比较了个别症状水平的ADM和心理治疗。我们搜索了PubMed Medline,Psycinfo和Cochrane Central Service的受控试验数据库,一个特定于心理治疗RCT的数据库,并寻找未发表的RCT。随机效应荟萃分析应用于SUM - 分数,用于抑郁症(HAM-D)和Beck抑郁库存(BDI)措施的汉密尔顿评级规模的个体症状。其次,我们计算了与患者的症状轮廓相结合的荟萃分析效果大小。使用来自慕尼黑抗抑郁症响应签名(MARS)研究的数据进行评估排序度量(N?= 407)和抑郁症对个体和组合治疗(预测)研究(n?= 234)的缓解的emory预测因子。系统审查确定了38个RCT,用于定性包涵体,27和19分别在总和分度水平上定量纳入,分别定量包含在HAM-D和BDI的个体症状水平上。荟萃分析策略均未显示出两种抑郁措施的ADM和心理治疗的有效性显着差异。排序度量没有显示MARS样本中的其他临床变量的有意义的关联,并且没有指示度量的效用,以便从预测数据进行更好的治疗分配。本已注册的报告显示,ADM和心理治疗的差异差异,用于治疗MDD和症状水平。基于症状的度量,如建议的排序度量不向这些处理提供信息,但是症状信息的预测值需要进一步测试其他治疗比较。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号